Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
Myriad Genetics (NASDAQ: MYGN) reported Q1 2026 revenue of $200.4 million, up 2% year‑over‑year, with gross margin at 68.7%. GAAP net loss was $34.1 million and adjusted EBITDA was $(4.5) million. The company reiterated full‑year 2026 guidance of $860–$880 million revenue and adjusted EBITDA of $37–$49 million. Key operational highlights include a 13% cancer care volume increase, a 15% decline in prenatal revenue, FDA approval of MyChoice CDx as companion diagnostic for Zejula, and the launch of Precise MRD.
Myriad Genetics (NASDAQ: MYGN) released the GeneSight Mental Health Monitor national survey on April 30, 2026. The survey finds patients with depression and/or anxiety report treatment feels "one-size-fits-all" and 88% would feel more confident with a personalized mental health care plan.
Other findings: 41% of medicated patients call treatment one-size-fits-all; 74% of those still finding a medication feel the same; 65% were unaware genetic testing could inform medication decisions.
Myriad Genetics (NASDAQ: MYGN) will release its first quarter 2026 financial results after market close on May 5, 2026, with a conference call and webcast at 4:30 p.m. ET the same day. Investors can join via live webcast on investor.myriad.com or by telephone after registration; an archived webcast will be available following the call.
Myriad Genetics (NASDAQ: MYGN) will present six abstracts, including two podium presentations, at the American Association for Cancer Research Annual Meeting on April 17-22, 2026 in San Diego. Highlights include MONITOR-Breast neoadjuvant ctDNA dynamics and a phase II adjuvant PD-1 trial, plus four poster presentations and a booth exhibit.
The company will showcase its Precise MRD tumor-informed MRD assay, MyRisk Hereditary Cancer Test with RiskScore, Prolaris, MyChoice CDx, and partnership offerings in biopharma development.
Myriad Genetics (NASDAQ: MYGN) announced that Japan's Ministry of Health, Labour and Welfare approved the MyChoice Test as a companion diagnostic for Lynparza (olaparib) in prostate cancer on April 14, 2026. The approval adds tumor-based HRD/BRCA testing access beyond prior breast and ovarian coverage under Japan's NHI.
This expands testing options for patients with metastatic castration-resistant prostate cancer and may increase identification of PARP inhibitor candidates in Japan.
Myriad Genetics (NASDAQ: MYGN) will present four research abstracts at the Society of Gynecologic Oncology Annual Meeting, April 10-13, 2026, in San Juan, Puerto Rico.
Key highlights: Precise MRD data showed post‑adjuvant ctDNA levels were significantly prognostic of ovarian cancer recurrence; three additional studies use the Myriad Collaborative Research Registry™ with de‑identified data from >1.3 million participants. Presentations and posters occur April 11–13; Myriad will exhibit at booth #523.
Myriad Genetics (NASDAQ: MYGN) announced FDA approval of the MyChoice CDx Test as the companion diagnostic for Zejula (niraparib) in advanced ovarian cancer in the United States. The approval is based on final PRIMA trial data and establishes MyChoice CDx as the only FDA-authorized CDx for Zejula.
The test uses next-generation sequencing to assess BRCA1/2 (including large rearrangements) and a tumor genomic instability score (LOH, TAI, LST) to determine HRD status for treatment decisions.
Myriad (NASDAQ: MYGN) launched the Precise MRD tumor-informed circulating tumor DNA (ctDNA) test on March 2, 2026, with a select group of community oncologists for patients with breast cancer.
The assay uses whole-genome sequencing to create personalized tests and enables ultrasensitive ctDNA detection down to one part per million. Myriad plans a broader U.S. commercial rollout later in 2026, with no limit on participating patients in the initial release.
Myriad Genetics (NASDAQ: MYGN) will present six abstracts at ASCO-GU Feb 26-28, 2026 reporting clinical performance for Precise MRD, Prolaris, and MyRisk oncology tests. Key data include ultra-sensitive ctDNA detection (below 100 ppm), a meta-analysis of 14 studies >8,000 patients showing Prolaris prognostic power, and germline testing results across Gleason and NCCN risk groups.
Findings are largely interim or preliminary but indicate potential diagnostic and prognostic value across genitourinary cancers.
Myriad Genetics (NASDAQ: MYGN) reported Q4 2025 revenue of $209.8 million and full‑year 2025 revenue of $824.5 million (down 2% YoY). Test volume was 382,000 in Q4, up 2% YoY. Q4 GAAP net loss was $7.9 million; adjusted EBITDA was $14.3 million. The company reiterated 2026 guidance of $860–$880 million revenue and 68–69% adjusted gross margin, with adjusted EBITDA guidance of $37–$49 million.
Management highlighted Prolaris, GeneSight, and three planned 2026 test launches (Precise MRD, AI-enabled Prolaris, FirstGene) as drivers for growth.